Humacyte Global, Inc.
Humacyte is pioneering a platform that enables the investigation, development, and manufacture of bioengineered human tissues and organs designed to be universally implantable, off-the-shelf, and regenerative, aiming to treat a wide variety of diseases, injuries, and chronic conditions.
Humacyte Global, Inc.
2525 E. Highway NC 54, Durham, NC 27713
Patents
What We Do
Acellular Tissue Engineered Vessel (ATEV™) is designed for the treatment of vascular trauma and has received priority review by the U.S. FDA.
Humacyte Acellular Tissue Engineered Vessel (ATEV™) has received FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for patients with Advanced Peripheral Artery Disease (PAD).
Humacyte Acellular Tissue Engineered Vessel (ATEV™) meets primary endpoints in V007 Phase 3 Clinical Trial in Arteriovenous Access for Hemodialysis.
Application Area
Funded Projects
Humacyte's Universally Implantable, Bioengineered Tissues Treat Injured in Ukraine
In March 2022, Ukrainian surgeons began requesting the "HAVs" for distribution to hospitals to treat patients with injuries including shrapnel wounds and mine blast injuries.
Humacyte’s Bioengineered Blood Vessel Implanted by Clinicians at Walter Reed to Restore Blood Circulation to Veteran’s Leg
Humacyte has bioengineered human acellular vessels (HAVs) that regenerate into living tissue, offering a groundbreaking vascular solution for military and civilian patients.